Belite Bio, Inc
BLTE
$165.93
$1.350.82%
NASDAQ
| 09/30/2025 | 12/31/2024 | 09/30/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.71M | 4.20M | 2.90M | 2.90M | 6.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.02M | 11.46M | 9.74M | 9.74M | 17.60M |
| Operating Income | -23.02M | -11.46M | -9.74M | -9.74M | -17.60M |
| Income Before Tax | -21.69M | -10.10M | -8.68M | -8.68M | -16.32M |
| Income Tax Expenses | -- | 0.00 | -- | 0.00 | -- |
| Earnings from Continuing Operations | -21.69M | -10.10M | -8.68M | -8.68M | -16.32M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.69M | -10.10M | -8.68M | -8.68M | -16.32M |
| EBIT | -23.02M | -11.46M | -9.74M | -9.74M | -17.60M |
| EBITDA | -22.97M | -11.42M | -9.71M | -9.70M | -17.56M |
| EPS Basic | -0.65 | -0.32 | -0.28 | -0.28 | -0.50 |
| Normalized Basic EPS | -0.41 | -0.20 | -- | -0.18 | -- |
| EPS Diluted | -0.65 | -0.32 | -0.28 | -0.28 | -0.50 |
| Normalized Diluted EPS | -0.41 | -0.20 | -- | -0.18 | -- |
| Average Basic Shares Outstanding | 33.22M | 31.46M | 30.69M | 30.69M | 32.59M |
| Average Diluted Shares Outstanding | 33.22M | 31.46M | 30.69M | 30.69M | 32.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |